ASX-Dividend-Report-Banner

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

March 13, 2024 11:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
Image source: Kalkine Media

SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering in in vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan.

TIDES Asia, a conference in Asia that brings together discovery, clinical, delivery and CMC/manufacturing experts developing therapeutics/vaccines using modalities of Oligonucleotides, Peptides, mRNA and Genome Editing. Attendees from US, Europe and Asia come together to share scientific strategies and common challenges to help accelerate new molecules to market.

YolTech Therapeutics' representatives will bring latest advancements in in vivo gene editing technology and innovative LNP deliver system during the conference. Sincerely invites partners, investors, and stakeholders to join the session at TIDES Asia 2024 to share views of our breakthroughs.

Details are as follows:

Date: Wednesday, March 20, 2024
Time: 1:30pm -2:00pm JST
Location: The Westin Miyako Kyoto - Higashiyama Ward, Kyoto, Japan
Track: Track 1

About YolTech
YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver system. It possesses strong capability of novel Cas and base editor discovery and exceptional in-house LNP production capacity for GMP manufactory, with independent intellectual property rights and core patent protection globally. It has created a pipeline with 10+ genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases as well as more common and rare diseases. Clinical trial clearance has been received for its leading in vivo gene editing asset YOLT-201 in March 2024.

For more information, please visit: www.yoltx.com or follow YolTech on LinkedIn https://www.linkedin.com/company/yoltech-therapeutics/

CONTACT: Wei Lu, [email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.